Oscar Health: $443M Loss in 2025, Now Promising a $750M Swing to Profitability. Is This Time Different?
Risk adjustment created a $275M surprise in a single quarter. The CEO says Oscar is "stronger than ever." Market share doubled to 30%. But the company has missed profitability promises before. Five lenses examine whether 2026 is finally the year.
Worst loss in company history
$750M swing from FY2025
Up from 17% in 2025
730 bps worse YoY
Oscar Health reported its largest annual loss ever in 2025: $443 million. The medical loss ratio deteriorated 570 basis points to 87.4% for the full year, with Q4 hitting an alarming 95.4% after a $275 million risk adjustment accrual true-up. This is the same company that entered 2025 guiding for profitability.
Management now projects a $750 million swing to profitability in 2026, with operating income guidance of $250-450 million. The numbers are large: 3 million paid members expected by Q1 end, revenue guided to $18.7-19.0 billion (up 61%), and market share that nearly doubled from 17% to 30%.
The question is straightforward: has Oscar earned the right to be believed? We ran five analytical lenses to find out.
Want the full 5-lens analysis with signal assessments and model debates?
Opus + Sonnet ensemble. 5 lenses. 8 signals. 6 debates. Full evidence citations.
Signal Assessments
Risk adjustment accruals created $275M Q4 true-up. CFO calls estimation 'the most difficult thing we do.'
CEO accumulating shares (+1.6M RSUs). Dual-class structure limits shareholder influence. CTO selling via 10b5-1.
$19B revenue guided, but dependent on ACA policy, member retention through subsidy cliff, and risk adjustment stability.
Entire business model depends on ACA economics. Subsidy expiration, CMS integrity, and risk adjustment create layered policy risk.
$5.5B cash mostly trapped in subsidiaries. $414M parent cash. $315M excess capital consumed in 8-10 months at loss rate.
Raised $885M (converts + revolver) during a loss year. Bold if 2026 delivers; imprudent if it doesn't.
CEO says 'stronger than ever' while reporting $443M loss. AI narrative is real but addresses SG&A, not the MLR problem.
$3.8B market cap appears to price in the 2026 turnaround. A second miss could trigger narrative collapse.
Key Findings
Risk Adjustment Is the Central Risk (4 Lenses Converge)
Four of five lenses independently identified ACA risk adjustment as the dominant threat to profitability. The Fugazi Filter flags it as an accounting estimation challenge. The Gravy Gauge shows it reducing net revenue per member. The Stress Scanner demonstrates it could consume the entire operating profit guidance. The Regulatory Reader identifies it as a structural feature of ACA design.
CEO Credibility Gap: A Pattern of Profitability Promises
Management has a documented pattern of promising profitability that fails to materialize. CEO Bertolini characterizes 2025 as a "reset year" and claims Oscar is "stronger than ever" while reporting the company's largest loss. The CFO provides more measured commentary, acknowledging risk adjustment difficulty. This CEO/CFO tone divergence is itself a signal.
"Oscar is stronger than ever. Our decisive actions in 2025 position us to take a significant leap forward on profitability."
"Estimating risk adjustment is the most difficult thing that we have to do each quarter because you're both trying to project your own performance and also the market."
Membership Growth Is Real, but Quality Is Shifting
Oscar enrolled 3.4 million members during open enrollment 2026 and expects 3.0 million paid by Q1 end (400K expected to churn from subsidy loss). Market share nearly doubled from 17% to 30%. Broker partnerships expanded 60%. These are genuine operational achievements.
The composition has fundamentally changed: silver plans dropped from 71% to 36%, bronze rose from 25% to 39%, gold quadrupled from 3% to 25%. Bronze members carry higher deductibles and historically higher churn. The average member is now 38, one year younger, affecting PMPM revenue.
AI Capabilities Are Genuine but Address the Wrong Problem
Oscar's AI is real and measurable: Oswell handles 86% of member questions, agentic AI reduced response times 67% during peak enrollment, and the company has "dozens of LLMs on the back end." SG&A improved 160 basis points to 17.5%.
The 2025 loss was driven by MLR deterioration (570 bps), not administrative costs. AI might help with care management and utilization steering over time, but the near-term profitability swing must come from pricing and risk selection. The technology moat is in admin efficiency, not underwriting.
Where Models Disagreed
Tech-Enabled Disruptor or Subsidized Growth Story?
Oscar is a policy-dependent insurer in tech clothing. Remove ACA subsidies, and the growth story collapses. The 2025 MLR miss occurred despite the technology platform.
AI and the +Oscar platform create real differentiation in retention and efficiency. SG&A improvements are tangible. Member satisfaction drives stickiness that competitors lack.
Resolution: Technology advantages are real in SG&A but have not solved the core insurance challenge of pricing and risk selection. The tech moat is in administrative efficiency, not underwriting.
Industry-Wide Reset or Company-Specific Failure?
Oscar's loss was outsized relative to peers, reflecting aggressive growth into populations with uncertain morbidity during a market shock.
All ACA carriers experienced MLR deterioration from Medicaid redetermination. This was an industry-wide morbidity shock, not company-specific.
Resolution: Both positions have merit. Medicaid impact was industry-wide, but Oscar's rapid growth amplified exposure. The Q4 $275M risk adjustment surprise specifically reflects the market share effect.
Cross-Lens Reinforcements
Risk adjustment is the central risk (4/5 lenses converge)
Accounting estimation, revenue quality, stress buffer, and regulatory structure all point to the same conclusion: risk adjustment volatility is the single most important variable.
Management credibility gap (3/5 lenses converge)
CEO optimism vs. CFO caution, accounting uncertainty making promises unreliable, and revenue quality shifts complicating projections all independently surface credibility concerns.
Subsidy dependency creates binary outcomes (3/5 lenses converge)
Revenue durability, regulatory exposure, and capital adequacy all hinge on the politically-determined enhanced premium tax credit question. Reinstatement is an immediate positive catalyst; continued expiration accelerates contraction.
What to Watch
Management expects Q1 to be the lowest MLR quarter. If Q1 exceeds 84%, the full-year guide of 82.4-83.4% is at risk. This is the first data point on whether 2026 pricing is adequate.
Target: 3.0M paid members by Q1 end. Below 2.7M would signal worse-than-expected subsidy cliff impact and undermine the revenue guidance foundation.
Any quarterly risk adjustment true-up exceeding $100M adverse would be a significant negative. The Q4 2025 $275M surprise is the cautionary precedent.
Any Congressional action to reinstate subsidies would immediately improve the membership, revenue, and market stability outlook. Political monitoring is essential.
Bottom Line
HIGHER SCRUTINY
Oscar Health has genuine competitive capabilities and impressive membership growth, but has not yet proven it can translate scale into sustained profitability. The 2026 guidance calls for a $750M earnings swing that depends on pricing adequacy, risk adjustment stability, and member retention through the subsidy cliff. Each of these variables carries meaningful uncertainty. The Q1 2026 results will be the credibility-defining data point.
Path to More Favorable Assessment
- • Q1 MLR at or below 83% (demonstrating pricing adequacy)
- • Paid membership at 3M+ by Q1 end
- • Risk adjustment tracking within 50 bps of 20% guide
- • Legislative action on enhanced premium tax credits
Path to Less Favorable Assessment
- • Q1 MLR above 84% (third consecutive miss)
- • Paid membership below 2.7M (worse-than-expected churn)
- • Risk adjustment true-up exceeding $100M adverse
- • Additional capital raise required before profitability
This analysis is for educational purposes only — it is not a recommendation to buy or sell any security.
Public Sources Used (16 documents)
Annual Report (10-K) — FY2025
Quarterly Reports (10-Q) — Q1-Q3 2025, Q3 2024
Current Reports (8-K) — 10 filings, 2025-2026
Proxy Statement (DEFA14A) — April 2025
Schedule 13D/A — Thrive Capital (3 filings)
Schedule 13G/A — Institutional Ownership (3 filings)
Q1-Q4 2025 Earnings Call Transcripts
Form 4 Insider Transactions — 20 filings
Form 144 Proposed Sales — 10 filings
CourtListener Litigation Search — courtlistener.com
Full Analysis with Signal Breakdowns
Explore the complete 5-lens assessment including debate transcripts, evidence citations, and monitoring triggers.
View OSCR Analysis